To study mesenchymal stem cells/multipotent stromal cells (MSC) at different stages of MM (Figure 1A, ii), we used a multicolor flow cytometry panel to identify cells lacking human lineage markers (CD2, CD3, CD14, CD16, CD19, CD56, CD235a), CD45, CD34 and HLA-DR, but expressing CD73, CD90 and CD105. This evidence concerns the gene NCAM1 and Miyoshi myopathy.